About This Site
This website provides a resource to healthcare providers to understand the Demand
Management Programme for Immunoglobulin and access guidance and materials to ensure
its effective implementation.
The shortage of immunoglobulin prompted the DH to develop a Demand Management Programme, with the objective of ensuring that supply is maintained, even in times of acute shortage, for the patients considered to be the highest priority because of a risk to life without treatment.
The Demand Management Programme consists of: Clinical guidelines to help potential prescribers of immunoglobulin identify treatment indications for which its use is appropriate [click Clinical Info tab], a demand management plan for immunoglobulin use, which recommends that trusts or strategic health authorities establish a local immunoglobulin assessment panel to approve and monitor the local prescribing of immunoglobulin [click Clinical Info tab], and also a national immunoglobulin database [click Ig Database tab]. The database will monitor immunoglobulin use to allow accurate forecasting, facilitate appropriate demand management, and provide a more accurate picture of prescribing by indication at national and local level.
The shortage of immunoglobulin prompted the DH to develop a Demand Management Programme, with the objective of ensuring that supply is maintained, even in times of acute shortage, for the patients considered to be the highest priority because of a risk to life without treatment.
The Demand Management Programme consists of: Clinical guidelines to help potential prescribers of immunoglobulin identify treatment indications for which its use is appropriate [click Clinical Info tab], a demand management plan for immunoglobulin use, which recommends that trusts or strategic health authorities establish a local immunoglobulin assessment panel to approve and monitor the local prescribing of immunoglobulin [click Clinical Info tab], and also a national immunoglobulin database [click Ig Database tab]. The database will monitor immunoglobulin use to allow accurate forecasting, facilitate appropriate demand management, and provide a more accurate picture of prescribing by indication at national and local level.
Whats New.....
February 2011: Ig Database version 4.0 launched
Version 4 of the National Immunoglobulin Database was launched on Friday 3rd February.
The new version incorporates changes that were requested by users and subsequently
approved by the national IVIG steering group. If you have any queries regarding
the new version or experience any difficulties with the new version please contact
us using the following email address : support@mdsas.com
You may download a full list of changes that have been incorporated into the new version. A document with screenshots illustrating the major changes is also included.
Immunoglobulin Database Workshop Presentation Slides
The presentation slides from the Immunoglobulin Database Workshop (15/12/2011) are now available.
Click Here for more information
April 2011: Urgent Product Safety Information
Urgent Product Safety Information - Vivaglobin All IVIg database users please read the letter form CSL Behring regarding the risk of thromboembolic events with subcutaneous or inappropriate intravenous use of Vivaglobin. Could you please forward this letter onto all healthcare professionals who are involved with the administration of IVIg at your centre.
August 2010: Ig Database version 3.0 launched
Version 3 of the
National Immunoglobulin Database was launched on Wednesday the 11th August. The
new version incorporates changes that were requested by users and subsequently approved
by the national IVIG steering group. If you have any queries regarding the new version
or experience any difficulties with the new version please contact us using the
following email address : support@mdsas.com
You may download a full list of changes that have been incorporated into the new version. A document with screenshots illustrating the major changes is also included.
March 2010: National Immunoglobulin Database Report Published (2008 - 2009)
The Department of
Health has published the First National Immunoglobulin Database Report (2008 - 2009).
Data presented are a unique, detailed view of current prescribing practice of immunoglobulin
in England. Seven NHS consultants, three commissioners and four database support
staff created this report under the direction of Dr Denise O'Shaughnessy of the
Blood Policy Unit, Department of Health and Carrock Sewell, Visiting Professor of
Immunology at the University of Lincoln in the period October - December 2009.
Although the findings presented are limited in scope in a number of ways, this report is important as it establishes, for the first time, a baseline of immunoglobulin use. This is a major step forward in establishing the Department of Health's Demand Management Programme, and in particular, validating the key step of prioritisation of treatment indications to ensure that immunoglobulin will always be available to those for whom the treatment is life - saving.
May 2009: Model Commissioning Policy
The National Specialised
Commissioning Group has published version two of the Model Commissioning Policy
for immunoglobulin (MCP). The policy provides a clear statement of the commissioning
position and the deci¬sion-making process for each category of treatment. These
documents can found by clicking the buttons below.
April 2009: Database Update Document
The Department of
Health has published a National Immunoglobulin Database Update. This update document
describes initial findings from the Database on immunoglobulin prescribing patterns,
includes information on the forthcoming Model Commissioning Policy for immunoglobulin
and offers a summary of the updated guidance on the use of immunoglobulin for measles
post-exposure prophylaxis issued by the Health Protection Agency. This document
can found on the DH website
here or by clicking the button below.